ATLyphe originates from an academic collaboration between ETH and UZH/USZ, aimed at developing a new anti-CD117xCD3 bispecific antibody for prevention of relapse and provide a safer and more precise conditioning prior to hematopoietic transplantation. Our new molecule engages and activates T cells, thus induces a potent killing of CD117 positive hematopoietic stem cells and leukemic blasts. Upon completion of our safety-focused phase I trial, a new study will be performed, investigating a revolutionary, less toxic approach to allogenic hematopoietic transplantation (i.e., replacing chemotherapy). Furthermore, a new technology will be implemented in our portfolio which will enable to quickly design personalized, targeted immunotherapies for several malignant diseases.